A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
This study examined the association between two specific polymorphisms of the gene encoding the mu-opioid receptor and treatment outcomes in alcohol-dependent patients who were prescribed naltrexone or placebo. A total of 82 patients (71 of European descent) who were randomized to naltrexone and 59 who were randomized to placebo (all of European descent) in one of three randomized, placebo-controlled clinical trials of naltrexone were genotyped at the A(+118)G (Asn40Asp) and C(+17)T (Ala6Val) SNPs in the gene encoding the mu-opioid receptor (OPRM1). The association between genotype and drinking outcomes was measured over 12 weeks of treatment. In subjects of European descent, individuals with one or two copies of the Asp40 allele treated with naltrexone had significantly lower rates of relapse (p=0.044) and a longer time to return to heavy drinking (p=0.040) than those homozygous for the Asn40 allele. There were no differences in overall abstinence rates (p=0.611), nor were there differences in relapse rates or abstinence rates between the two genotype groups among those assigned to placebo. These preliminary results are consistent with prior literature demonstrating that the opioid system is involved in the reinforcing properties of alcohol and that allelic variation at OPRM1 is associated with differential response to a mu-receptor antagonist. If replicated, these results would help to identify alcohol-dependent individuals who may be most likely to respond to treatment wit…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An initial retrospective analysis of NTX trials found that OPRM1 influenced treatment response, such that individuals with the Asp40 variant (G allele) receiving NTX had a longer time until the first heavy drinking day and were half as likely to relapse compared to those homozygous for the Asn40 variant (A allele) [92].”
From Relapse prevention for addictive behaviors (2011) · cites this paper as [92]
In the citing paper
“Interestingly, both human A118G subjects and Rhesus C77G subjects are more likely to respond positively to opioid antagonist therapy for alcoholism, which suggests that the differences in receptor properties may be a direct physiological mechanism for the increased risk for alcoholism (Oslin et al 2003).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Oslin et al 2003
Citations
Cites
(1996) · Cited by 6,884
The fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222 · cited 1×
“The Addiction Severity Index (ASI) was used to measure the severity of alcoholrelated problems during the pretreatment period (McLellan et al, 1980, 1992).”
MethodSelf-citationSobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodMcLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Self-citationNew Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503 · cited 1×
“…lifetime and recent (past 30 days) severity of problems in seven areas of biopsychosocial functioning (represented by component scores): medical status, employment and self-support, alcohol use, drug use, legal status, family and social relations, and psychiatric symptoms (McLellan et al, 1985).”
BackgroundSelf-citationNaltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487 · cited 4×
“Although this definition of heavy drinking has been used in a number of pharmacotherapy trials (O’Malley et al, 1992; Volpicelli et al, 1992; Anton, 1996; Kranzler and VanKirk, 2001), both higher and lower levels of consumption could be considered significant.”
BackgroundMethodInfluentialBond, C., LaForge, K. S., Tian, M., Melia, D., Zhang, S., Borg, L., Gong, J., Schluger, J., Strong, J. A., Leal, S. M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9608 · Cited by 1,074 · cited 3×
“…association between OPRM1 sequence variation and the presence of alcohol and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001;…”
BackgroundInfluentialSOBELL, L. C., SOBELL, M. B., LEO, G. I., & CANCILLA, A. (1988) · British Journal of Addiction · doi:10.1111/j.1360-0443.1988.tb00485.x · Cited by 776 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodNaltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618 · cited 1×
“…advantage of naltrexone over placebo (O’Malley et al, 1992; Volpicelli et al, 1992; Oslin et al, 1997; Chick et al, 2000; Anton et al, 2001; Monti et al, 2001; Morris et al, 2001), other studies have failed to show a significant drugplacebo difference (Kranzler et al, 2000; Krystal et al, 2001).”
Background
Research works printed but not linked: 2
- Thomas C, Wallack S, Swift R, Bishop C, McCarty D, Simoni-Wastila L (2001). Adoption of naltrexone in alcoholism treatment. J Addict Dis 20: 180.
- Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP (1997). BRENDA Manual: Compliance Enhancement Techniques with Pharmacotherapy for Alcohol and Drug Dependence. Guilford press: Philadelphia.
Cited by
Items 501–572 of 572
POST MORTEM STUDIES ON THE HUMAN ALCOHOLIC BRAIN: DNA METHYLATION AND MOLECULAR RESPONSES
Johansson, S. (2008) · Figshare · Cited by 2
de Bejczy, A. (2016) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Johnson, B. A., & Ait‐Daoud, N. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_47 · Cited by 1
4 Stoornissen in en door het gebruik van psychoactieve stoffen
Schippers, G. M., & van den Brink, W. (2008) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-6632-3_4 · Cited by 1
(2005) · Clinical Toxicology · doi:10.1080/07313820500207624 · Cited by 1
NEUROPEPTIDE Y (NPY) AND GLUTAMATE TRANSPORTER (GLAST) IN BEHAVIORAL MODELS OF PSYCHIATRIC DISORDERS
Karlsson, R. (2008) · Figshare · Cited by 1
The Pharmacogenomics of Addiction
Goldman, D. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_11
Using Neuroscience to Guide the Development of New Pharmacotherapies for Alcoholism
Krishnan‐Sarin, S., O’Malley, S. S., & Krystal, J. H. (2009)
Pharmacological Approaches to the Treatment of Alcohol Dependence in the Young
Johnson, B. A. (2011) · Wiley eBooks · doi:10.1002/9781118785089.ch16
Functional Characterization of the OPRM1 A118G Single Nucleotide Polymorphism in Mice
Mague, S. D. (2011) · ScholarlyCommons (University of Pennsylvania)
Evidence-based pharmacotherapy of illicit substance use disorders
van den Brink, W. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.013
The public health implications of genetic research on addiction
Mathews, R. R. S., Hall, W., & Carter, A. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139058971.012
TREATMENT OF ADDICTION IN THE ERA OF GENOMIC MEDICINE
O’Brien, C. P. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.02001.x
Self-citationPharmacogenetics - A Treatment Strategy for Alcoholism
Munshi, A., & Sharm, V. (2012) · InTech eBooks · doi:10.5772/33779
Björk, K. (2008) · Figshare
The Pruritus of Cholestasis: ten years into the 21th Century
Bergasa, N. V. (2011) · Medicina Universitaria
Kops, M. S. (2009) · Utrecht University Repository (Utrecht University)
IMAGEN: IMPLICATIONS FOR ADDICTION SCIENCE AND SCIENCE POLICY
Heilig, M. A. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.02004.x
Intérêt de la pharmacogénétique en psychiatrie
Ramoz, N., Voegeli, G., & Gorwood, P. A. P. M. (2014) · Springer eBooks · doi:10.1007/978-2-8178-0505-4_3
L’importance du génome sur la pharmacologie des opiacés
Landau, R. (2006) · Le Praticien en Anesthésie Réanimation · doi:10.1016/s1279-7960(06)75644-3
De neurobiologie van verslaving
Schipper, R., & Naarding, P. (2014) · Tijdschrift voor Neuropsychiatrie en Gedragsneurologie · doi:10.1007/s40533-014-0017-y
Peter Riederer “70th birthday” Neurobiological foundations of modern addiction treatment
Jacob, C. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0886-8
Pharmacotherapeutic interventions in alcohol and illicit drug dependence
Lingford-Hughes, A. R., & Welch, S. (2006) · Psychiatry · doi:10.1053/j.mppsy.2006.10.011
O’Brien, C. P. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0034-y
Self-citationGenetics of Alcohol Dependence in Humans: Recent Findings and Perspectives
Preuss, U. W., Walther, C. A. P., & Wong, J. (2012) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911.a000157
Molecular Genetics and the Treatment of Addiction
Ray, L. A., & Hutchison, K. E. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_55
Avaliaçăo do efeito da Mianserina sobre o padrăo de consumo de álcool em camundongos /
Jamal, Y. (2008) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Epigenetic Dysregulations in the Brain of Human Alcoholics : Analysis of Opioid Genes
Bazov, I. (2016) · Uppsala University Publications (Uppsala University)
Pharmacotherapies for Drug Addiction
Gipson, C. D., & Kalivas, P. W. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00357
Functional imaging of neural systems associated with alcohol reward and amphetamine toxicity
Dudek, M. (2016) · Helda - University of Helsinki Institutional Repository · Cited by 1
Exploring variation of mu-opioid receptor gene and subjective opioid effects in healthy men
Maurud, H. (2014) · NORA - Norwegian Open Research Archives
The Role of the Opioid System in Reward Responsiveness
Eikemo, M. (2012) · NVA (Nasjonalt vitenarkiv) · Cited by 1
The new pharmacotherapies for alcohol dependence
Mason, B. J., & Jacobs, M. B. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511782107.021
Naltrexone and Opioid Antagonists for Alcohol Dependence
Pettinati, H. M., Dundon, W. D., & López, M. J. C. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398338-1.00039-7
Self-citationGenetics of Substance Use, Abuse, Cessation, and Addiction
Uhl, G. R., Walther, D. M., & Drgon, T. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418679-8.00002-2
A Novel, Unexpected Treatment for Alcoholism
O’Brien, C. P. (2012)
Self-citationPharmacotherapies for the Treatment of Alcohol Dependence
Wright, T. M., Baros, A. M., & Anton, R. F. (2007) · Elsevier eBooks · doi:10.1016/b978-008044927-2/50056-0
Beck, A., Grace, A. A., & Heinz, A. (2011) · Wiley eBooks · doi:10.1002/9781119998938.ch5
Farmakoterapia wspomagająca w leczeniu uzależnienia od alkoholu i narkotyków
Swift, R. M., & Leggio, L. (2013) · Wydawnictwa Uniwersytetu Warszawskiego eBooks · doi:10.31338/uw.9788323513759.pp.287-312 · Cited by 1
Exploring genetic predictors of naltrexone treatment response in opioid use disorder
Blokhina, E. A., Krupitsky, E. M., Kibitov, A. O., Palatkin, V., Yaroslavtseva, T. V., Verbitskaya, E. V., & Zvartau, E. E. (2019) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2019-4-1-61-64
Goldman, D. A., Landi, P., & Ducci, F. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00119-1 · Cited by 1
Teuns, G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813724-6.00049-9
Alcohol and Drug Dependence Treatment: Pharmacogenetics
Anton, R. F. (2014) · Springer eBooks · doi:10.1007/978-3-642-27772-6_7032-1
Traditional treatment strategies for alcoholism and the withdrawal symptoms
Singh, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819680-9.00004-4
Chapter 9. Treatment of Alcohol-Related Disorders
Braxton, A., Wright, T., & Myrick, H. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615373970.kb09
Anjum, A. (2016) · Springer eBooks · doi:10.1007/978-1-4939-2528-5_14
Bazov, I., & Bakalkin, G. Y. (2016) · Epigenetics and human health · doi:10.1007/978-3-319-29901-3_3
(2013) · CRC Press eBooks · doi:10.1201/b15462-35
Heilig, M. A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-045396-5.00059-2
Brock, D. C., Tofighi, B., Lee, J. D., & Fastenberg, J. H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4779-5_5 · Cited by 1
Symbiotic Relationship of Pharmacogenetics and Drugs of Abuse
Rutter, J. L. (2008) · Springer eBooks · doi:10.1007/978-0-387-76678-2_4
Alcohol and Drug Dependence Treatment: Pharmacogenetics
Anton, R. F. (2015) · Springer eBooks · doi:10.1007/978-3-642-36172-2_7032
O’Brien, C. P. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.006
Self-citationAlcohol Use Disorders: Leveraging Informatics to Improve Patient Care
Hwang, C., & Williams, L. (2022) · Translational bioinformatics · doi:10.1007/978-981-16-7893-6_2 · Cited by 1
Hong, M., Khemiri, L., Guterstam, J., Franck, J., Jayaram‐Lindström, N., & Melas, P. A. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00707-8
Deciphering the Role of Genetics in Alcohol Use Disorder
Legaki, E., Koutromanos, I., Mantonakis, L., Tzavellas, E., & Gazouli, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-73368-0_119
Naltrekson i behandlingen av alkoholavhengighet
Bramness, J. G. (2025) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.25.0514
Chapter 3. Alcohol Use Disorder
Kranzler, H. R., Knapp, C. M., & Hartwell, E. E. (2025) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894550862.lg03
Self-citationJönsson, S. (2012) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Love, T. (2010) · Deep Blue (University of Michigan)
To Open Up New Vistas in Basic and Preclinical Addiction Research
Spanagel, R. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0338-9_75
Molecular Adaptations in the Endogenous Opioid System in Human and Rodent Brain
Hussain, M. Z. (2013) · Uppsala University Publications (Uppsala University)
Spreer, M. (2024) · Qucosa (Saxon State and University Library Dresden)
Genomic Predictors of Treatment Response in Substance Use Disorders
Mahajan, P. (2025) · Indian Journal of Private Psychiatry · doi:10.5005/jp-journals-10067-0198
Miroshkin, S., Skryabin, V. Y., Pozdnyakov, S. A., Ivanchenko, V. A., Шипицын, В. В., & Масякин, А. В. (2026) · Современная терапия психических расстройств · doi:10.48612/psyph/5z4v-34ma-7bgt
Herbina, N., Рубан, О. А., Bernatonienė, J., Pudžiuvelytė, L., & Maslii, Y. (2022) · Lithuanian University of Health Sciences
Réévaluation de l'apport du nalméfène au traitement de l'alcoolodépendance
Palpacuer, C. (2018) · theses.fr (ABES) · doi:10.70675/aa77e495z482ez45b0z9aabz3b0862e3413e
Bases génétiques des troubles du contrôle des impulsions dans la maladie de Parkinson
Bekadar, S. (2021) · theses.fr (ABES) · doi:10.70675/2479c7b7zf902z4f82zb884z73019fdf9661
Marinelli, S., Delfino, D. A., Pelagatti, E., Ciccarelli, A., Piersanti, V., & Ricci, P. (2026) · La Clinica Terapeutica · doi:10.7417/ct.2026.2051
Jääskeläinen, I. P. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1898127
“Pharmacogenetic studies have linked the OPRM1 A118G polymorphism to therapeutic response to naltrexone (Oslin et al., 2003; see also Chamorro et al., 2012) and increased hedonic response to alcohol (Ray et al., 2012), consistent with the hypothesis that inter-individual differences in opioid…”
BindingDB Entry 50037757: Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
BindingDB (2012) · UC San Diego · doi:10.7270/q2416xtd
Evidence-based pharmacotherapy of nicotine and alcohol dependence
van den Brink, W. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.012
Metadata
- Authors
- Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P.
- Affiliations
- University of Pennsylvania (US)
- University of Connecticut (US)
- Yale University (US)
- Corresponding author
- Oslin, David W
- Venue
- Neuropsychopharmacology
- Published
- 2003-04-23
- Volume
- 28
- Issue
- 8
- Pages
- 1546-1552
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2074406420
- Cited by
- 571
- References
- 50
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 9 · 2020: 13 · 2019: 18 · 2018: 13 · 2017: 13 · 2016: 20 · 2015: 31 · 2014: 36 · 2013: 34 · 2012: 58
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- University of Pennsylvania
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health (5r01aa011062-05, AA03510)
- U.S. Public Health Service
- National Institute on Alcohol Abuse and Alcoholism (AA11330, AA-07517, R01AA011330, AA 13736, AA-03510, K24AA013736, AA 11062)
- National Institute of Mental Health (K08MH001599, MH 01599)
- National Institute on Drug Abuse (R01DA014008, DA 11385, DA 14008, DA001586)
- National Center for Research Resources (RR-06192, M01RR006192)
- NIH Clinical Center
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- mu-opioid receptor, OPRM1, naltrexone, alcoholism, genetic polymorphism, treatment response, relapse, abstinence, opioid system, pharmacogenetics
- MeSH terms
- Adult, Alcoholism, Female, Gene Frequency, Humans, Male, Middle Aged, Naltrexone, Polymorphism, Genetic, Confidence Intervals, Logistic Models, Odds Ratio, Survival Analysis, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.